2 Results for "

RVT 3101

" in MedChemExpress (MCE) Product Catalog:
Products (2)

2 Results for "RVT 3101" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P990876
CAS No.: 2911580-96-4
Synonyms: PF-06480605 (WT IgG1); RVT-3101 (WT IgG1)
Target:  

TNF Receptor NF-κB IFNAR

Research Areas:  

Inflammation/Immunology

Afimkibart (PF-06480605) (WT IgG1) is a fully human monoclonal antibody that selectively inhibits trimeric tumor necrosis factor-like ligand 1A (TL1A). Afimkibart (WT IgG1) is a monoclonal antibody that retains the native, wild-type IgG1 Fc structure without any engineered modifications; unlike Afimkibart (HY-P990876A), it does not contain the L234A, L235A, or G237A mutations. Afimkibart (WT IgG1) can be used for the research of inflammatory bowel disease .
loading...
    loading...
Cat. No.: HY-P990876A
Synonyms: PF-06480605; RVT-3101
Target:  

TNF Receptor NF-κB IFNAR

Research Areas:  

Inflammation/Immunology

Afimkibart (PF-06480605; RVT-3101) is a humanized monoclonal antibody targeting TL1A (TNFSF15). Afimkibart blocks the TL1A‑DR3 signaling axis by neutralizing the TL1A ligand, inhibits the release of pro-inflammatory cytokines, suppresses NF-κB activation and IFN-γ production, and simultaneously attenuates fibroblast activation and fibrosis progression associated with this pathway. The Fc region of Afimkibart contains the mutations L234A, L235A, and G237A, which are designed to reduce the binding of the antibody to FcγR and C1q, thereby attenuating or eliminating the antibody’s ADCC and CDC effector functions. Afimkibart is applicable to research on immune inflammation-related conditions, such as ulcerative colitis .
loading...
    loading...